VisionPoint Advisory Group’s Ligand Pharmaceuticals LGND Stock Holding History

VisionPoint Advisory Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Buy	+1,043	New	+$246K	0.05%	333

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Portside Wealth Group Provo, Utah $858M AUM 26.82% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

VisionPoint Advisory Group's LGND Position: Q2 2026 in Review

VisionPoint Advisory Group opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,043 shares worth $330K. The stake represents 0.05% of the portfolio and ranks #333 among its holdings.

36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

VisionPoint Advisory Group held 1,043 shares of Ligand Pharmaceuticals worth $330K as of Q2 2026.
Ligand Pharmaceuticals was a new VisionPoint Advisory Group position in Q2 2026.
Ligand Pharmaceuticals made up 0.05% of VisionPoint Advisory Group's portfolio in Q2 2026, its #333 holding.
36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.